Sumitomo Pharma Co., Ltd.

DB:DPM Stock Report

Market Cap: €1.4b

Sumitomo Pharma Management

Management criteria checks 2/4

Sumitomo Pharma's CEO is Toru Kimura, appointed in Jan 2016, has a tenure of 8.92 years. directly owns 0.02% of the company’s shares, worth €270.47K. The average tenure of the management team and the board of directors is 2.3 years and 4 years respectively.

Key information

Toru Kimura

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure8.9yrs
CEO ownership0.02%
Management average tenure2.3yrs
Board average tenure4yrs

Recent management updates

Recent updates

CEO

Toru Kimura (64 yo)

8.9yrs

Tenure

Mr. Toru Kimura, Ph D., is Representative Director, President & CEO of Sumitomo Pharma Co. Ltd. from June 25, 2024.Mr. Toru serves as Director at Sumitomo Pharma America, Inc. since 2024. He served as Rep...

Leadership Team

NamePositionTenureCompensationOwnership
Toru Kimura
Representative Director8.9yrsno data0.020%
€ 270.5k
Motoyuki Sakai
Representative Director and Executive VP of Corporate Planningless than a yearno datano data
Hiroyuki Baba
Mngg Exec. Officer of Global Data Design7.7yrsno data0.0015%
€ 20.8k
Naoki Noguchi
Executive Officer of Corporate Governance & Communications2.7yrsno datano data
Yoshiharu Ikeda
Managing Executive Officer of Drug Research Division4.5yrsno data0.0038%
€ 52.1k
Koichi Kozuki
E.O. of R. Aff.1.9yrsno datano data
Shigeyuki Nishinaka
Managing Executive Office7.7yrsno data0.0020%
€ 27.7k
Isao Shimizu
Executive Officer1.9yrsno datano data
Kenji Ueno
Executive Officer1.9yrsno datano data
Hideyuki Harada
Managing Exe. Officer of Tech. R&D Div.3.7yrsno datano data
Tsutomu Nakagawa
Executive Officer1.9yrsno data0.00076%
€ 10.5k
Yumi Sato
Exe Off of Drug Dev Div1.9yrsno datano data

2.3yrs

Average Tenure

64yo

Average Age

Experienced Management: DPM's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Toru Kimura
Representative Director8.5yrsno data0.020%
€ 270.5k
Motoyuki Sakai
Representative Director and Executive VP of Corporate Planningless than a yearno datano data
Yoshiharu Ikeda
Managing Executive Officer of Drug Research Division4.5yrsno data0.0038%
€ 52.1k
Tsutomu Nakagawa
Executive Officerless than a yearno data0.00076%
€ 10.5k
Saeko Arai
Independent Outside Director6.5yrsno datano data
Minoru Usui
Independent Outside Director3.5yrsno datano data
Nobuhiro Endo
Independent Outside Director5.5yrsno datano data
Hiroshi Niinuma
Directorless than a yearno datano data
Takashi Kutsunai
Full-Time Audit & Supervisory Board Member6.5yrsno data0.0065%
€ 90.1k
Yoshio Iteya
Outside Audit & Supervisory Board Member6.5yrsno datano data
Hisayoshi Kashima
Full-Time Audit & Supervisory Board Member1.5yrsno data0.0035%
€ 48.5k
Koji Fujimoto
Independent Outside Director2.5yrsno datano data

4.0yrs

Average Tenure

66yo

Average Age

Experienced Board: DPM's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 12:55
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sumitomo Pharma Co., Ltd. is covered by 24 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Ritsuo WatanabeBofA Global Research
Hidemaru YamaguchiCitigroup Global Markets Japan Inc.